💊 NASH Treatment: Review Of Current And Future Therapies For Non-Alcoholic Steatohepatitis скачать в хорошем качестве

💊 NASH Treatment: Review Of Current And Future Therapies For Non-Alcoholic Steatohepatitis

🔍 Join Professor Stephen Harrison (USA) as he explores current and future therapies for Non-Alcoholic Steatohepatitis (NASH). 🩺 Revisit PanNash's most-watched webinar and immerse yourself in the future of NASH treatment. Dive deep with renowned hepatology expert Professor Steven Harrison into the forefront of NASH therapeutic advancements and the extensive drug development landscape. 💡Get insights into the potential of NASH therapeutics in precision medicine, and understand the role of combination therapies in providing a comprehensive approach to NASH treatment. Highlighted are: ➡️ NASH Pathology: An in-depth look at NASH, its connection to metabolic disorders, and its implications for potential treatments. ➡️ Therapeutic Advancements: An examination of the latest therapies for NASH, including an analysis of their effectiveness and limitations. ➡️ Drug Development Landscape: A snapshot into the intricate process of NASH drug development, spotlighting recent advancements and future innovations. 🔗 More info available: https://pannash.org/nash-videos/nash-... 00:00 Introduction 03:50 NASH: Potential Therapeutic Targets 04:54 Targeting NASH: Exploring Therapeutic Approaches 06:09 Agents in Phase 2 Development-Route of Administration 08:14 Agents in Phase 3 Development 08:43 NASH Development Landscape 08:46 Fibrosis Improvement 09:19 Compounds in Phase 2 10:41 Compounds in Phase 3 12:34 NASH Resolution Compounds in Phase 2 13:32 NASH Resolution Compounds in Phase 3 14:14 Both NASH Resolution AND Fibrosis Improvement 14:22 Investigating Phase 2 Compounds 15:17 Exploring Phase 3 Compounds 15:39 Advancements in NASH Cirrhosis Studies 16:46 The Future of NASH Therapeutics Ongoing Phase 3 Trials 17:55 Key Insights from Past Failures: An Essential Part of the Drug Development Journey 18:07 Agents may have different profiles of histopathologic effects (fibrosis, NASH resolution) vs Extrahepatic Effects 20:58 First NASH Drugs in Development 21:24 Combination Therapy in NASH Treatment 22:27 Ideal Combination 23:57 Phase 2 Combination Therapy Trials 24:05 Categorizing NASH Therapeutics by Mechanism of Action (MOA) 25:32 Future Therapeutic Considerations for Precision Medicine 👨‍⚕️ Dr. Stephen A. Harrison, President of Summit Clinical Research, is a recognized authority in hepatology with over 20 years of experience. Distinguished for his dedicated service in the medical field, Dr Harrison is known for his pivotal research and advancements in the treatment of liver diseases, including non-alcoholic steatohepatitis (NASH). His commitment to research, education, and patient care has significantly influenced the landscape of NASH therapeutic strategies. ------------------------------------------------------------ The PanNASH™ initiative aims to increase awareness and disseminate knowledge related to NASH (non-alcoholic steatohepatitis) as a multisystem disease focusing on PPAR agonists among the scientific and clinical community, patients and other key stakeholders within the healthcare system, thus improving the lives of millions of patients worldwide. Learn as much as possible to seek quality for better NASH care. ✉ SIGN-UP to receive our newsletter and/or our free science magazine: https://pannash.org/newsletter/ FOLLOW US: LinkedIn:   / about   Twitter:   / pannash_init   CHECK OUT FOR FREE MORE EDUCATIONAL NASH VIDEO content obtained from expert doctors worldwide: https://pannash.org/videos/ LAST COMMENTED ARTICLES: https://pannash.org/commented-articles/